Obintuzumab and rituximab variants with reduced ADCP

摘要

The present invention relates to modified antibodies. In particular, the invention relates to recombinant monoclonal antibodies or fragments, including chimeric, primatized or humanized antibodies or fragments, with reduced effector function and altered ability to mediate cell signal activity by the target antigen. Furthermore, the invention relates to nucleic acid molecules encoding such antibodies, as well as vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention and methods of using these antibodies in the treatment of diseases. 【Selection chart】 None